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Summary 
HIM-1 replicates more efficiently in cultured IL-2-depen- 
dent CD4 T cells expressing VJH2 T cell receptors 
(TCRs) rather than other TCRs (Laurence et al., 1992). 
A viral reservoir is frequently established in Vp12 T 
cells in HIV-l-infected patients. Here we show that cy- 
tomegalovirus (CMV) is responsible for Vl~12-selective 
HIV-1 replication that is indistinguishable from the ef- 
fect of known superantigens (SAGs). This effect is de- 
pendent on direct contact of T cells with CMV-infected 
monocytes. CMV infection, but not iel or ie2 transfec- 
tion, reproduces this effect in a monocytoid cell line 
(U937). In HIV-infected patients, the presence of CMV 
antibodies correlates with an HIV-1 viral load preferen- 
tially skewed to the Vp12 subset. Together, these data 
suggest that a CMV gene product is responsible for a 
SAG-driven Vp12-selective HIV-1 reservoir in vivo. 
Introduction 
Acquired immunodeficiency syndrome (AIDS) is a retrovi- 
ral disease of pandemic proportions. Worldwide more than 
200 million individuals are infected with the human immu- 
nodeficiency virus (HIV). Despite a vigorous immune re- 
sponse on the part of the host, HIV infection leads to the 
gradual destruction of the immune system, primarily by 
depleting CD4 T lymphocytes in infected hosts. HIV viral 
isolates replicate most efficiently in activated CD4 T cells. 
In patients, CD4 T cells carry the majority of the viral load 
(Seshamma et al., 1992). To explain the paradox of a virus 
eliminating its own cellular reservoir, one may invoke other 
cellular reservoirs such as monocytes, dendritic cells, or 
follicular dendritic cells in lymph nodes, which might act 
as a source of infectious virions to infect new CD4 T cells 
(Pantaleo et al., 1993; Embretson et al., 1993; Cameron 
et al., 1992). However, at least in peripheral blood and 
lymph nodes, the predominant host cell in which HIV-1 
DNA is found is the CD4 T cell (Schnittman et al., 1989; 
Embretson et al., 1993). 
An alternative possibility is that some CD4 T cells do 
act as a reservoir and are not deleted. Recently, HIV-1 
DNA and infectious virus were found specifically concen- 
trated in a tiny subset (10-2o)  of CD4 T cells in many 
infected patients (Dobrescu et al., 1995). This subset ex- 
pressed T cell antigen receptors (TCRs) using the V!B12 
gene segment. For instance, in 16 of 23 HIV-infected pa- 
tients there was a 2- to 360-fold higher viral load in fresh, 
uncultured V~12 cells than in control V~6.7a cells (Do- 
brescu et al., 1995). HIV-1 in VI312 cells of patients was 
competent in an infectivity assay (Dobrescu et al., 1995). 
Moreover, irradiated non-T cells from HIV-infected pa- 
tients stimulated proliferation of V~12 but not V~6.7a cell 
lines (Laurence et al., 1992). In addition, HIV-I replicates 
approximately 100-fold more efficiently in interleukin 2 
(IL-2)-dependent T cell lines expressing TCR VI312 rather 
than other VI~ genes, regardless of the major histocompati- 
bility complex (MHC) type of the cells (Laurence et al., 
1992). HIV-1 replication occurred preferentially in V~12 T 
cells, as compared with 11 other VI3 subsets, from normal 
fresh peripheral blood mononuclear cells cultured for 6-8 
days with IL-2 (Dobrescu et ai., 1995). Therefore the V1~12 
subset serves as a preferential host cell for HIV-1 replica- 
tion, possibly because it is activated by a superantigen 
(SAG)-Iike moiety presented to T cells by MHC class II- 
expressing non-T cells. 
SAGs are a group of microbial proteins known for their 
potent ability to activate large numbers of T cells that share 
common TCR V~ expression, and this is typically indepen- 
dent of the MHC class II alleles used by antigen-presenting 
cells. Mouse mammary tumor viruses (MMTVs) are B-type 
retroviruses that encode the prototypic viral SAG in the 3' 
long terminal repeat. The SAG directly supports the initial 
stages of viral infection after vertical transmission via ma- 
ternal milk. The SAG bridges antigen-presenting cells 
bearing MHC class II and large numbers of T cells express- 
ing specific VI~ genes. It is thought that both cell types 
transduce signals as a consequence and the net effect is 
massive immune activation with high levels of lympho- 
kines produced (Chatila and Geha, 1993). As a direct con- 
sequence, MMTV replication in infected B cells is up- 
regulated, and cellular proliferation of virally infected B 
cells accounts for a 4000-fold increase in the number of 
infected B cells by clonal expansion (Held el: al., 1993, 
1994). 
While previous studies suggested the presence of an 
HIV-1 associated SAG (Laurence et al., 1992; Dobrescu 
et al., 1995), they did not establish the source of the puta- 
tive SAG gene: HIV-1 itself, a ubiquitous virus, and the 
host cell were all equally likely alternatives (Posnett et al., 
1993a). Here, we provide evidence that the V~12-specific 
SAG is produced by cytomegalovirus (CMV)-infected 
monocytes, that its production is driven by CMV infection 
even in the absence of HIV-1, and that CMV antibodies 
in patients positive for HIV-1 are associated with an HIV-1 
reservoir in VI312 cells. 
Results 
Vp12-Selective HIM-1 Replication Resembles 
the Effect of Known SAGs 
HIV-1 replication in V~12 cell lines required the presence 
of non-T cells and was inhibited with anti-M HC II antibodies 
(Laurence et al., 1992). Selective HIV replication in the 
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Figure 1. Non-T Cells Can Stimulate V~-Selec- 
tive HIV-1 Replication Just like Exogenous 
SAGs 
(A) Controls for standard curves are a 10-fold 
dilution of ACH2 cells (1 HIV genome per cell) 
in a constant number (105) of uninfected CEM 
cells (left) and 5-fold dilutions of 104 ACH2 and 
10 ~ CEM cells (right). The insert represents 
log,0 optical density (OD) values from gag 
(closed circles) and HLA-DQ~ bands (open cir- 
cles) of the 5-fold dilution series, plotted 
against the known number of HIV-1 copies (Yl) 
or total cell number (y2). These linear curves 
have regression coefficients close to 1.0 and 
were used for extrapolations of the experimen- 
tal data to calculate HIV-1 copies per 1000 cells 
(see Figure 2). 
(B) T cells from a normal HIV-l-negative donor 
were infected with TIIIB (moi, 0.05) and cul- 
tured with autologous or allogeneic non-T cells. 
The non-T cells were previously exposed tothe 
mitogen NalO4 or were not. After 7 days, the 
indicated V~ subsets were positively selected 
or depleted (minus) with magnetic beads prior 
to cell lysis and PCR. 
(C) HIV-infected T cells were cocultured with 
autologous non-T cells pulsed with myco- 
plasma arthritidis mitogen (MAM) (Bhardwaj et 
al., 1994) or with DAP-DR1 transfectants ex- 
pressing MTV7 or MTV9 (Labrecque et al., 
1993). Dilutions of the PCR product are indi- 
cated. 
VI512 subset of freshly infected normal T cells cultured for 
6-8 days with IL-2 also required non-T cells (Dobrescu et 
al., 1995). To examine the effect of different sources of 
non-T cells, fresh T cells from a normal adult donor were 
infected with HIV-1 (TIIIB, multiplicity of infection [moi], 
0.05) and cultured with autologous non-T cells or alloge- 
neic non-T cells (plus or minus prior treatment with NalO4) 
for 7 days. HIV-1 replication, measured by semi-quantitative 
polymerase chain reaction (PCR) in isolated VI~ subsets, 
occurred preferentially in VI312 cells in three of four condi- 
tions (Figure 1 B). Normalized for cell numbers, there were 
approximately 100-fold more viral gag copies in VI312 cells 
compared with control subsets (Figure 2B). The same pat- 
tern of V~-selective HIV-1 replication was also observed 
with known SAGs (Figure 1C): mycoplasma arthritidis mi- 
togen, which targets V1~17 T cells (Friedman et al., 1991), 
or MMTV SAGs of mammary tumor virus 7 (MTV7) and 
MTV9, which target human V~12 and V~6.7a subsets, re- 
spectively (Labrecque et al., 1993). In each case, the SAG- 
targeted VI3 subset contained 10- to 100-fold greater num- 
bers of HIV-1 copies per 1000 cells (Figure 2C). These 
measurements are normalized for cell numbers and there- 
fore underestimate the total impact of the SAG on the viral 
load, as SAGs are known to expand cell numbers of the 
targeted Vl5 subset in short-term cultures (Kappler et al., 
1989; Friedman et al., 1991; Labrecque et al., 1993). Fig- 
ures 2A and 2C contain controls in which the ratio of HIV-1 
per total cell number remains constant through serial 5-fold 
dilutions, indicating the degree of experimental variation 
in the measurements and demonstrating that the ratios are 
independent of the total numbers of cells in each positively 
selected VI~ subset. 
Vp12-Selective HIM-1 Replication Depends 
on the Presence of Monocytes from 
CMV-Seropositive Donors 
Any MHC class II-positive cell is thought to be capable 
of presenting a SAG to T cells. However, in Figure 3, we 
show that only CD14 +monocytes were capable of support- 
ing selective HIV-1 replication in V~12 cells. CD19 ÷ B cells 
and CD19-14- dendritic cells were insufficient, although 
both express MHC class II and can present exogenous 
SAG. Dendritic cells are particularly efficient at presenting 
SAGs to T cells (Bhardwaj et al., 1992). Epstein-Barr vi- 
rus-transformed B cell lines were also ineffective (data 
not shown). Since monocytes from normal adults are often 
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Figure 2. Calculated Copies ofHIV-1 per 1000 Cells Derived from the 
Data in Figure 1 
The selected standards allow quantitation of the total cell numbers in 
each VI3 subset and control for variable total cell numbers in each V~ 
subset. 
(A) The measurements for the left-most closed bar and the stippled 
bars (from Figure 1A) all contain ratios of 100 ACH2 cells per 1000 
CEM cells, but with variable total cell numbers present. The extrapo- 
lated values approximate 100 HIV-1 copies per 1000 cells, and the 
mean - SD is indicated (open bar). Bycontrast, the 10-fold dilutions 
of ACH2 in a constant 10 ~ CEM is far more sensitive for gag detection, 
and the calculated ratios using the selected standard curves are inac- 
curate. 
(B) Shows that there are 35- to 70-fold more gag copies in VI~12 cells 
than contro~ subsets after correction for cell numbers. 
(C) Shows a similar degree of skewed HIV-1 replication toward the 
V(3 subset targeted by each of three known SAG. V~12s and VI312p 
represent positive selection with twodifferent V~B 12-specific antibodies 
($511 and p4-21). The 1:5 and 1:25 dilutions of the PCR product dem- 
onstrate that our calculations of HIV copies per 1000 cells are not 
dependent on variable amounts of PCR product loaded on the gels. 
MAM, mycoplasma rthritidis mitogen. 
HLA-DQ - 
HIV1 gag * 
Figure 3, HIV-1 Replication in V[B12 Cells Depends on the Presence 
of CD14 ÷ Monocytes 
Isolated T cells f rom an HIV-negative donor infected with TIIIB (moi, 
0.05) were cultured for 7 days with the indicated non-T cell populations, 
which were added to a f ixed number  of T cells (2 x 106). The yield 
of the different non-T cell fractions varied, and dif ferent numbers were 
added to the T cells as indicated by the percentages of total cells in 
culture. CD19 CD14 cells are enriched in blood dendrit ic cells (10O'o - 
20%).  Each non-T cell population was isolated by cell sorting and 
treated with NalO4 prior to culture. VI~ subsets were posit ively selected, 
and T cells depleted of V~12 (but containing all other V~ subsets) were 
also obtained for PCR analysis. 
persistently infected with human CMV (Taylor-Wiedeman 
et al., 1991 ; Soderberg et al., 1993) and can express imme- 
diate-early genes of CMV after in vitro culture (Ibanez et 
al., 1991; Taylor-Wiedeman et al., 1994), we considered 
the possibility that CMV was the source of the SAG. 
Non-T cells were able to promote selective HIV-1 replica- 
tion in V~12 cells, as shown in Figure 1B, only when ob- 
tained from CMV-seroposit ive donors (Table 1). Non-T 
cells from human cord blood and from CMV-negative adult 
donors were unable to stimulate HIV-1 replication in V~12 
cells, even when the non-T cells had received prior treat- 
ment with the mitogen NalO4 (see Experimental Proce- 
dures) or when an al logeneic combination of non-T cells 
and HIV-infected T cells was used (Table 1; Figure 4). 
CMV-negative cord blood non-T cells were perfectly capa- 
ble of presenting an exogenous SAG (mycoplasma arthrit- 
idis mitogen), resulting in HIV-1 replication in the targeted 
V~17 subset (Friedman et al., 1991) (data not shown). 
Several CMV Isolates Can Stimulate HIV-1 
Replication in Vl~12 Cells 
The monocyte-l ike cell line, U937, is permissive for CMV 
infection (Numazaki et al., 1992) and expresses low levels 
of HLA-DR5 (data not shown). These cells do not contain 
endogenous CMV and transcribe CMV immediate-early 
genes (immediate-early 1 [iel] and ie2) within 24 hr after 
infection (see Figures 9B and 9C; data not shown). U937 
cells were infected with CMV (moi, 1) in a 3-day culture 
fol lowed by treatment with mitomycin C to inhibit further 
cellular proliferation. The CMV-infected U937 cells were 
then added, at a 1:10 ratio, to freshly isolated normal T 
cells infected in vitro with HIV-1. CMV-infectecl U937 cells 
Cel l  
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Table 1. Non-T Cells Activate HIV Replication in Vl312 Cells Only when Derived from CMV + Donors 
Blood Donors from Whom Non-T 
Cells Stimulate VI312 Selective 
Culture Conditions HIV-1 Replication 
CMV-seropositive donors (n = 9) 
HIV-infected T cells plus autologous non-T cells 
HIV-infected T cells plus autologous NalO4-treated non-T cells 
HIV-infected T cells plus allogeneic non-T cells 
HIV-infected T cells plus allogeneic NalO4-treated non-T cells 
CMV-seronegative donors (n = 8) 
HIV-infected T cells plus autologous non-T cells 
HIV-infected T cells plus autologous NalO4-treated non-T cells 
HIV-infected T cells plus allogeneic non-T cells 
. HIV-infected T cells plus allogeneic NalO4-treated non-T cells 
2 of 9 (22%) 
5 of 9 (55%) 
3 of 8 (38%) 
5 of 8 (75%) 
0 of 5 (0%) 
0 of 7; (0%) 
o of 4 (0%) 
0 of 3 (0%) 
Non-T cells were isolated from donors that had been serologically tested (by enzyme-linked immunosorbent assay) for antibodies to CMV. The 
irradiated cells were cocultured under four different conditions with HIV-infected T cells. PCR was performed on isolated V~ subsets after 6-8 
days (as in Figure 1B). Indicated are the percentage ofdonors with non-T cells that support V~12-selective HIV.1 replication. 
efficiently stimulated selective HIV-1 replication in VI312 
cells, but uninfected U937 cells or NalO4-treated U937 
cells did not (Figures 4-6). 
The CMV effect was not dependent on the viral isolate 
used (Figure 4). Laboratory strain AD169 and clinical iso- 
lates 1165 and 2830 were equally capable of stimulating 
H IV-1 replication in VI312 T cells from CMV-negative donor 
(MU) and cord blood (CB). 
Up-regulated HIV-1 replication in VI512 cells was ob- 
served with three unrelated HIV-1 isolates: TIlIB, JRFL, 
and BaL (Figure 5; data not shown). HIV-1 replication oc- 
curs predominantly in the VI312 subset, since VI312- 
depleted cells showed significantly decreased viral repli- 
cation compared with VI317-depleted cells (Figure 5). 
The CMV effect could no longer be observed when the 
CMV viral stock was inactivated by exposure to ultraviolet 
(UV) light prior to infection of U937 cells (Figure 6A). CMV 
DNA replication is usually initiated 2-3 days after infection 
(reviewed by Mocarski, 1993). Since U937 cells were har- 
vested 3 days after CMV infection and then treated with 
mitomycin C, which inhibits DNA replication, the ffect on 
V1~12 cells was expected to be independent of CMV DNA 
replication. In fact, addition of phosphonoformic acid 
(Foscarnet), a specific inhibitor of CMV DNA replication, 
or acyclovir to CMV-infected U937 cells did not inhibit the 
SAG-like effect (Figure 6A). Finally, cycloheximide, added 
12 hr prior to harvesting CMV-infected U937 cells, partially 
inhibited the SAG-like effect in a dose-dependent manner 
(Figure 6A). Protein synthesis in CMV-infected U937 cells 
was therefore required to observe the Vl312-specific SAG 
activity. 
HLA-DQ - 
HIV-1 gag - 
Selective HIV-1 Replication in VI]12 T Ceils Requires 
Cell Contact with CMV-Infected U937 Cells 
SAGs must be bound to MHC class II molecules expressed 
at the cell surface of antigen-presenting cells for efficient 
T cell responses. Thus, T cells and antigen-presenting 
cells form obligatory cell-cell contacts. Consistent with 
this mode of activation of VI312 cells, and inconsistent 
with the effect of a soluble molecule such as a cytokine, 
coculture of CMV-infected U937 cells in transwells with 
HIV-l-infected T cells failed to activate VI312-specific 
HIV-1 replication (Figure 6A). Moreover, addition of recom- 
binant tumor necrosis factor (~ (TNF(~), a monocyte cy- 
tokine known to up-regulate HIV-1 replication potently 
(Clouse et al., 1989a, 1989b; Smith et al., 1992; Hober 
et al., 1992), induced replication in all three VI5 subsets 
examined, rather than in a VI512-selective pattern, and 
antibody to TNFa did not inhibit the ffect of CMV-infected 
U937 cells (Figure 6B). 
The transwells were separated by a 0.3 ilm filter. The 
result in Figure 6A, therefore, argues against the possibil- 
ity that CMV virions (150-200 nm) are transmitted from 
U937 to T cells and that CMV and HIV-1 might coinfect 
the same host cells. In fact, CMV DNA could not be found 
by PCR in isolated VI312 cells or other VI3 subsets after 
a 7-day coculture of T cells with CMV-infected U937 cells 
(data not shown). 
CMV-Infected U937 Cells Stimulate Vp12 CD4 ÷ and 
V1~12 CD8 + Cells to Expand In Vitro 
SAGs added to T cell cultures produce an expansion of 
the targeted VI3 subsets (Kappler et al., 1989; Friedman 
Figure 4. Three Different Isolates of CMV 
Each Promote HIV-1 Replication in VI312 T 
Cells 
TIIIB-infected T cells from two CMV-negative 
donors were cocultured for 7 days with autolo- 
gous NalO4-treated non-T cells or U937 cells 
infected (or not) with the indicated CMV iso- 
lates at reel 1. The low level HIV-1 replication 
in VI3 subsets other than VI312 (donor CB) is 
presumably due to dissemination of HIV-1 
within the cultures. 
HLA-DQ - 
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Figure 5. Replication of Two Different HIV-1 
Isolates in V~12 Cells I Stimulated by CMV 
HIV-1 (TIIIB or JRFL)-infected cord blood T 
cells (moi, 0.05) were cultured for 8 days as 
indicated with NalO4-treated autologous non-T 
cells or with U937 cells infected (or not) with 
CMV AD169. Positively selected V~, subsets 
(plus) and T cells depleted (minus) of either 
V~12 or V~17 were analyzed for HIV-1 load. 
et al., 1991). Therefore, we analyzed the percentage of 
V~ 12 cells in cocultures of HIV-l- infected T cells with autol- 
ogous NalO4-treated non-T cells from a CMV-positive do- 
nor. Uncultured fresh CD3÷CD4 ÷ cells contained 2% V~12 
cells. After 7 days, there were 18% Vl~12 cells (data not 
shown). Next, normal T cells were cultured with either 
U937 or CMV-infected U937 cells in the absence of HIV-1 
for 6 days and then stained. There were 1.5% versus 8.1% 
VI~ 12 per total CD3 cells, respectively, as assayed with two 
different V1312-specific monoclonal antibodies (MAbs) 
(Figure 7). There was no increase in the' percentages of 
three other V~ subsets. The relative expansion of the VI312 
subset involved both CD4 and CD8 cells. This result ar- 
gues in favor of a SAG response as opposed to a pept ide-  
MHC response, which would be either class I or class II 
restricted and would therefore involve either CD8 or CD4 
cells, but not both. Moreover, this extent of specific expan- 
sion of a VI~ subset is not expected in responses to nominal 
peptide antigens. 
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Evidence of a VJ~12-Specific SAG In V ivo 
in CMV- In fected  Pat ients 
A group of 23 HIV-l- infected patients was studied using 
HIV-1 gag DNA semi-quantitative PCR (Dobrescu et al., 
1995) (Table 2). About two thirds of these patients had a 
2- to 360-fold higher viral load in V1312 than in V~6.7a cells. 
In several patients, HIV-1 DNA was selectively present in 
VJ312 cells at repeated timepoints. For example, in patient 
M3 the viral load is strongly skewed to the V~12 and 
V[35.2/3 subsets, while several other V~ subsets lack de- 
tectable HIV-1 gag (Figure 8). This is not due to variable 
cell numbers in the positively selected V~ subsets, as the 
HLA-DQ bands are similar and the VI3 subsets assessed 
by flow cytometry are comparable (the range is 1%-6% of 
CD3+CD4 ÷ T cells). The V~12 subset is one of the smaller 
subsets in this patient (1%-2% of CD3+CD4 ÷ T cells). It 
is unknown whether the relatively high HIV-1 copy number 
in the VI35.2/3 subset is a consistent finding in this patient• 
It is not related to the CMV SAG response, since we had 
Figure 6. The CMV Effect on HIV-1 Replica- 
tion in V~12 Cells I Not Due to TNFa, Requires 
Cell-Cell Contact, and Requires Live CMV and 
Protein Synthesis in CMWlnfected Host Cells, 
but Does Not Require CMV DNA Replication 
(A) HIV-l-infected T cells were cocultured for 
7 days with U937 cells. In conditions 3 and 4, 
U937 cells were separated from the T cells in 
a transwell system (0.3 p.m filter; Costar). In 5, 
the CMV viral stock was UV irradiated (1 J/cm 2 
i~g,'ml mpg/ml UV-C at 254 nm). U937 cells were infected with 
: ~ ~ ~ 01 ~ ~ ~ CMV AD169 and cultured for 3 days in the pres- 
=. >>> >>> ence of Foscarnet 100 pg/ml (condition 6) or 
' U937 U937 0.1 mM acyclovir (condition 7). Cycloheximide ~9 
vi, (CHX) was added to AD169-infected U937 cells 
8 9 for the last 12 hr of the 3-day culture (8 and 9). 
(B) HiV-l-infected cord blood T cells were cul- 
tured for 7 days with U937 cells treated with 
NalO4 (11) or with CMV AD169-irffected U937 
cells (12-14), to which were added rabbit anti- 
TNF~ (30 ng/ml; Sigma)(12), rabbit i mmunoglob- 
ulin (30 ng/ml) (13), or exogenous human re- 
combinant TNFa (10 ng/ml; R&D Systems) (14). 
Cell 
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Figure 7. U937 Cells Infected with CMV Selectively Stimulate VI312 
CD4 and Vt312 CD8 Cells 
Fresh T cell from an HIV-l-negative donor were cocultured with U937 
or CMV-infected U937 cells at a 10:1 ratio. After 7 days, the cells were 
stained by two-color immunofluorescence with CD3-PE, CD4oPE, or 
CD8-PE and VI~ MAbs indirectly labeled with goat anti-mouse Ig-fluo- 
rescein isothiocynate (Posnett et al., 1993b). 
previously examined this subset in in vitro cultures, as in 
Figure 1, without observing high level HIV-1 viral replica- 
tion (Dobrescu et al., 1995). 
The skewed distribution of HIV-1 gagto  the VI312 subset 
was a consistent feature in three samples taken from pa- 
tient M3 over a 1.3 year period. The VI512 subset was not 
deleted in M3 or any of our patients (Posnett et al., 1993b). 
Therefore, this subset appears to act as a viral reservoir 
in some patients like M3 (Dobrescu et al., 1995). 
Serum antibodies to CMV were examined in this group 
of patients (Table 2). There was a highly significant correla- 
tion between CMV antibodies and high V~12 to V~6.7a 
viral load ratios (Table 2). In contrast, there was no correla- 
tion with antibodies to other viruses (Epstein-Barr virus, 
hepatitis B, and hepatitis C). Thus, CMV infection is asso- 
ciated with HIV-1 DNA selectively enriched in VI312 cells 
in vivo. 
A 
HLA-DQ - 
HIVlgag - 
O O ~O' l " -  ~ O ~" O'}',,- 03, (~T'- ¢~1QO '~ I',,- O3 'w- O, I I  
"- 8 >> > I 
HIV-1 copies I Posit ve y se ected V~ subsets I 
B HIV-1 copies in various VI3 subsets (patient M3) 
Date of sample 12/92 3/93 3/94 
V~12 242 836 1022 
Vf~,6.7a <10 <10 <10 
VI~B <10 <10 <10 
V(~13.1 <10 <10 <10 
V~17 ND 62 <10 
V(~3 ND ND <10 
V~5.1 ND ND 48 
V~5.2/3 ND ND 652 
V~7.1 ND ND <10 
V~19 ND ND <10 
V~21 ND ND <10 
V~22 ND ND <10 
Figure 8. Skewed HIV-1 Viral Load in Patient M3 
(A) HIV-1 gag load in positively selected VI3 subsets obtained freshly 
ex vivo in March, 1994. 
(B) HIV-1 copy numbers in various indicated V[5 subsets obtained by 
extrapolation on to the gag standard curve. The data were obtained 
from samples collected at he indicated timepoints (Dobrescu et al., 
1995). ND, not done. 
Is the Vp12-Specific SAG a CMV Product? 
To determine whether CMV immediate-early gene prod- 
ucts transactivate a host ceLl gene (Stinski, 1978) responsi- 
ble for the VJ~12 SAG effect, i e l  and ie2 were transfected 
into U937 cells (Figure 9). The expression vectors, pON2205 
IE1491aa and pON2206 IE2s~gaa (Jenkins et al., 1994), use 
the SRa promoter, which lacks the crs cis repression se- 
quence of the ie l / ie2 promoter. An alternative transcript 
for IE2338a~ would also be present in CMV-infected ceils, 
but not in the IE2~79~-transfected cells. It is expressed as 
a late gene product and can act as a strong repressor for 
IE1 and IE2 by binding to crs (Jenkins et al., 1994). The 
PCR primers used in Figure 9C amplify a 279 bp fragment 
of exon 5 shared by both IE2 transcripts. 
Figures 9B and 9C show that the transfectants ex- 
pressed mRNA by reverse transcription-PCR (RT-PCR). 
While infected U937 cells promoted HIV-1 replication spe- 
cifically in VI312 cells, IE2579aa-transfected cells up- 
regulated HIV-1 replication in all three VI3 subsets tested, 
and IE1491aa-transfected cells did not augment HIV-1 rep- 
lication in any subset (Figure 9A). The nonspecific HIV- 
1-activating effect of IE2s~ga~-transfected U937 cells may 
be repressed in CMV-infected U937 cells. 
These results and the failure to detect the SAG effect 
with NalO4-treated U937 cells together suggest that a 
CMV-encoded gene is responsible for the SAG effect 
rather than a transcriptionally activated host cell gene. 
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Table 2. Correlation between Positive CMV Serology and Skewing 
of the HIV Viral Load to the Vp,12 Subset 
HiV Load Ratio 
Patient CMV EBV HPC HPB VJ312/VI36.7 a 
M1 + ND ND - 360.0 
M3 + ND ND - 68.3 (>100) 
042 + + + 34.5 
006 + + + + 13.3 
017 + ND + + 13.3 (2.9) 
001 + + + + 10.0 
033 + + + + 8.3 
015 ND ND + + 6.1 (2.6, 3.3) 
012 + IgM + + + 5.7 (4.8) 
025 - + + + 5.0 
041 + + + + 4.9 
040 + IgM + + + 4.8 
007 + ND + + 4.5 
005 + + + + 3.5 
024 - + + + 3.0 
009 - + + + 2.2 
018 - ND ND + 1.8 (1.2) 
016 + ND + + 1.5 
014 - + + + 1.4 (0.5) 
013 - + + ND 1.1 
038 - + + + 1.0 
031 - + + + 0.6 
039 - + + + 0.3 
Serum CMV antibodies were measured by enzyme-linked immunosor- 
bent assay (ELISA; Diamedix microassay). Titers greater than 1:21 
were reported as positive. Positive titers are IgG except where indi- 
cated. IgG titers for Epstein-Barr virus (EBV) were measured in an 
indirect fluorescence test and considered positive if greater than 1: 
10; hepatitis C (HPC) antibodies were measured by ELISA (Abbott); 
hepatitis B (HPB) antibodies were measured by radioimmunoassay 
(Abbott). The correlation between CMV serology status and the HIV-1 
load was significant: p < 0.0039 by logistical regression analysis. 
a The ratio was calculated from data on HIV-1 copies per 1000 cells 
in each V~ subset. Ratios from repeat samples obtained at intervals 
of 3-9 months are indicated in parentheses. The patients are listed 
in order of viral load skewing to the V~12 subset. All patients were 
hemophiliacs except for M1, M3, and 006. The data on viral load have 
been described previously (Dobrescu et al., 1995). 
Discussion 
We demonstrate here that the HIV-1 viral reservoir in V1~12 
cells is related to a Vl~12-specific SAG-like activity pro- 
duced by CMV-infected monocytes. Just as known SAGs, 
the monocyte-derived SAG directs efficient HIV-1 replica- 
tion to a specific VI3 subset, perhaps leading to a viral 
reservoir in these cells. These findings are reminiscent of 
studies on the role of MMTV SAG (Held et al., 1993, 1994). 
Previous Examples of Viral SAGs 
There are two groups of MMTVs, the infectious exogenous 
milk-borne retroviruses, which are vertically transmitted, 
and the endogenous variants, which are integrated in the 
mouse genome. MMTV sag genes each differ in the C-ter- 
minal portion encoding the SAG protein, a type II trans- 
membrane protein. The C-terminal sequence determines 
the V~ specificity of the SAG and interacts directly with 
TCR residues (Korman et al., 1992; Acha-Orbea et al., 
1993; Marrack et aL, 1993). Each inbred mouse strain 
carries a different set of endogenous sag genes and de- 
letes the SAG-targeted VI3 subsets during thymic ontog- 
eny prior to birth. Since the target VI3 subset is required 
for the exogenous virus to infect the neonatal host suc- 
cessfully (Golovkina et al., 1992; Held et al., 1993), the 
evolutionary argument is that mice can protect themselves 
from infection by integrating the viral sag genes and pass- 
ing them on to their progeny (Coffin, 1992). To date, how- 
ever, integration of dozens of viral sag genes in mice has 
no parallel in other species. In fact, evidence of endoge- 
nous SAGs is lacking in rats and humans (Smith et al., 
1992; Baccala et al., 1992). Observations on genetic varia- 
tion in the expressed human VI~ repertoire are apparently 
due to MHC genes and the TCR genes themselves (Pos- 
nett, 1995). 
Another example of a viral SAG has been described, 
the N protein of the rabies virus nucleocapsid (Lafon et 
al., 1992, 1994). The unprocessed SAG binds to MHC 
class II (z chains and stimulates human VI~8 T cells. In 
mice, it targets V~6 cells. Mice lacking the VI~6 gene are 
partially resistant to rabies, as assessed by the absence 
of clinical paralysis 13 days after infection with rabies virus, 
and when Vl36 T cells are adoptively transferred, all the 
mice develop paralysis (Lafon et al., 1994). It is not known 
whether natural host animals (foxes, racoons, skunks, 
bats, coyotes, and wolves) harbor rabies virus with SAG 
activity and whether their TCR repertoires show V13 dele- 
tions typical of endogenous SAGs. It is also not known 
whether animals lacking the target VI~ subset (Vl36 in se- 
lected mice) are less likely to transmit rabies virus to new 
hosts and whether Vl~-specific activation amplif ies the vi- 
ral load. 
A Role for a CMV SAG 
We have provided evidence for a CMV-driven SAG that 
targets human Vl312 cells. While this is likely a CMV- 
encoded gene product (as discussed above), the alterna- 
tive possibility, that it represents a human endogenous 
SAG gene transcriptionally activated by CMV infection, is 
also of interest, as numerous endogenous human retrovi- 
ruses could possibly serve this function. 
A CMV-driven SAG specific for V~12 cells as proposed 
here would represent the first example of a herpesvirus 
SAG, with wide-reaching implications for host-pathogen 
relationships in humans, as several herpesviruses com- 
monly infect the large majority of adults worldwide. A SAG 
might, for instance, stimulate lymphoproliferation in the 
infectious mononucleosis syndrome of primary CMV or 
Epstein-Barr virus (Smith et al., 1993) infection and in 
primary HIV infection associated with CMV coinfection 
(Oksenhendler et al., 1993). 
The V1~12 subset does not appear to be preferentially 
deleted in vivo in CMV-seroposit ive individuals (Laurence 
et al., 1992; Posnett et al., 1993b). In humans, natural 
exposure to a SAG, such as TSST-1 in toxic shock syn- 
drome, does not lead to persistent detectable deletion of 
the reactive (V~2) subset (Choi et al., 1990). Moreover, 
the putative Vp12-specific SAG may simply not be ex- 
pressed in persons latently infected with CMV. However, 
in the setting of in vitro cultures, particularly with NalO4 
activation of monocytes, expression of the SAG is likely 
activated. With HIV infection, CMV genes are known to 
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Figure 9. CMV Immediate-Early Transactiva- 
tore (IE1 and IE2) Are Insufficient To Induce 
the V1312 SAG Effect 
(A) U937 cells were either infected with AD169 
or transfected with pON2205 (IE1) or pON2206 
(IE2) (Jenkins et el., 1994) and then cocultured 
with HIV-infected T cells for 7 days. 
(B) RT-PCR for IE1 4 days (or 1 day, in lanes 
3 and 4) after infection or transfection ofU937 
cells. 
(C) RT-PCR for IE2 1 day after infection or 
transfection. MRC5 are fibroblaets used to 
grow CMV stocks, gDNA, genomic DNA. 
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be transcriptionally activated (Skolnik et al., 1994; Ho et 
al., 1991), which might result in SAG production and selec- 
tive HIV-1 replication in the V1312 subset. In vivo, this would 
establish an HIV-1 viral reservoir in VI312 cells (Dobrescu 
et al., 1995). Future studies need to focus on how these 
cells escape apoptosis and direct cytopathic effects of 
HIV-I. 
The proposed role of the CMV-driven SAG is similar to 
the role of SAGs produced by exogenous MMTV, which 
are involved in the amplification of the viral load in the 
earliest stages of infection after milk-borne vertical trans- 
mission of virus from mothers to pups (Golovkina et al., 
1992; Held et al., 1993). However, the MMTV-encoded 
SAG benefits the original virus, rather than assisting a 
heterologous virus. Therefore, a role for activated V1312 
cells in CMV infection itself is likely. 
One idea is that production of infectious CMV from la- 
tently infected monocytes requires T cell help. Previous 
attempts to reactivate latent CMV infection from blood 
monocytes in vitro have been remarkably unsuccessful 
(Taylor-Wiedeman et al., 1994). However, in a culture sys- 
tem of primary monocytes, which relies on contacts with 
mitogen-stimulated T cells, productive CMV infection was 
observed (Ibanez et al., 1991). A SAG could provide the 
same conditions. By bridging V1~12 cells and monocytes 
(via TCR and MHC class II) both cell types would be po- 
tently activated (Chatila and Geha, 1993) and local con- 
centrations of lymphokines would be elevated. This also 
occurs in an allo-response in which a large number of T 
cells bind the allogeneic target cells (via TCR and MHC). 
This is in effect what happens in allo-mismatched trans- 
plantation, a common clinical scenario for CMV reacti- 
vation. 
Transactivation of HIV-1 via CMV ie gene products has 
been suggested as the mechanism for cooperation be- 
tween CMV and HIV-1 (Davis et al., 1987). This would 
require the presence of both transcriptionally active vi- 
ruses in the same cell, which is probably a rare event 
(Nelson et al., 1988; Laurence, 1990). Thus, a firm mecha- 
nistic explanation is lacking. CMV-dependent production 
of a SAG may explain why CMV is a potent cofactor for 
HIV-1 replication in vitro (Skolnik et al., 1994). Whether 
CMV infection accelerates clinical progression of HIV-1 
infection (Webster et al., 1989; Hirsch et al., 1984; Rabkin 
et al., 1993) or increases the susceptibility to HIV infection 
after initial exposure are questions that deserve further 
investigation. 
Experimental Procedures 
Cell Cultures and Isolation of Subsets 
Peripherat blood mononuclear cells were isolated by density centrifu- 
gation. T cells and non-T cells were separated by rosettin 9 with neura- 
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minidase-treated sheep erythrocytes. T cells were infected with HIV-1 
TIIIB isolate (moi, 0.05). Non-T cells were treated, where indicated, with 
4 mM NalO, (sodium periodate) for 15 rain at 4°C and then irradiated at 
3000 rads. Non-T cells were then added back to the infected T cells 
(106 per milliliter) at a 1:10 ratio (non-T:T) and cultured for 6-8 days 
in medium containing 10% FCS and IL-2 (50 U of NIH/BRMP per 
milliter; BTI Research Reagents) added on days 3-4 of culture. V~ 
subsets were isolated by incubating T cells (106 cells per VI3 MAb) 
with V~-specific MAb (Posnett et al,, 1993b) for 45 min, followed by 
three washes with PBS and a second incubation with goat anti-mouse 
Ig-coated magnetic beads (Dynal) at 20 beads per target cell for 30 
min on ice. Cells adherent o the beads were separated using a magnet 
and washed with PBS. Cells depteted of a V!3 subset (efficiency, 750/0 - 
100%) were obtained by collecting the nonadherent cells. Once iso- 
lated, the subsets (approximately 104 cells per subset) were immedi- 
ately lysed to prepare DNA in 50 i11 of 10 mM Tris (pH 8.0), 1 mM 
EDTA, 0.001% Triton X-100, 0.0001% SDS, 600 ~.g/ml proteinase K 
at 56°C for 1 hr, followed by 95°C for 15 min. The isolation of VI~ 
subsets from patient blood samples was previously described (Do- 
brescu et al., 1995). 
The mitogen NalO4 had been used to treat non-T feeder cells for 
maintenance of cloned and uncloned human T cell lines (Laurence 
et al., 1992). Fresh non-T ceils from CMV-seropositive donors that 
are not treated with NaIO4 can provide a strong stimulus for HIV-1 
replication in VI312 cells (Dobrescu et al., 1995). This SAG-like effect 
is usually augmented after NalO4 stimulation of non-T cells (Dobrescu 
et al., 1995), presumably because of nonspecific up-regulation of 
mRNA in the NalO4-treated cells. 
U937 cells were infected with CMV isolates (moi, 1) and cultured 
for 3 days under the indicated conditions. They were then treated with 
mitomycin C (50 ~g/ml for 1 hr at 37°C) to inhibit further cell prolifera- 
tion and were cocultured with freshly HIV-l-infected normal T cells at 
a cell ratio of 1:10 (or 1:100) for 6-8 days prior to isolation of V~ subsets 
for PCR. 
Viral Isolates and Infections 
Three HIV-1 viral isolate stocks were used, TIIIB, JRFL, and BaL, with 
a concentration of t0 ~ TCID per milliliter. The stocks were prepared 
in mycoplasma-free CEM cells or in PHA-treated T cell blasts. For 
infections, 1 x 10 ~ to 5 x 107 freshly isolated T cells were washed 
twice in PBS and resuspended in 3 ml of RPMI, 10% FCS, and virus 
was added at an moi of 0.05. The T cells were incubated at 37°C at 
5% CO2 for 2 hr. The unincorporated virus was removed by washing 
three times in PBS, and cells were then cultured under the indicated 
conditions. 
Three CMV viral isolates were used to infect U937 monocytic ells, 
AD169 (laboratory strain), 1165, and 2830 (clinical isolates from Dr. 
David Emanuel). U 937 cells (106) were washed once in PBS and resus- 
pended in 1 ml of CMV stock (106 TCID per milliliter), incubated for 
2 hr at 37°C at 5% CO2, washed once in PBS, and then cultured for 
3 days. 
Transfections 
U937 monocytic cells were grown overnight in RPMI, 10% FCS with 
antibiotics at a concentration of 0.5 x 106 U937 per milliliter. The U937 
cells were then washed in RPMI. U937 cells (3 x 106) resuspended 
in 0.8 ml of RPMI were transferred to Gene Pulser Cuvettes (Bio-Rad) 
with 5 #g of DNA and DEAE Dextran (10 p.g/ml), iel and ie2 DNA 
was prepared from peN2205 and peN2206, kindly donated by Dr. Ed 
Mokarski (Jenkins et al., 1994). Cells were electroporated at 250 V, 
960 ~F and at a time constant between 12-13.9 s. 
HIV-1 PCR 
One half of the lysate from each V6 subset (25 ~1) was used for a 50 
pl PCR reaction containing 10 mM Tris (pH 9), 50 mM KCI, 0.01% 
gelatin, 0.1% Triton X-100, 3.5 m M MgCI2, 0.4 mM dNTPs, 2 U of Taq 
polymerase (Promega), 106 cpm of kinased sense gag primer, 10 ~ 
cpm of kinased sense HLA-DQe primer, and equal molar ratios of the 
corresponding unlabeled antisense primers (about 10 pmol of gag 
primers and 1 pmol of HLA DQ primers per PCR reaction). Primers 
were labeled with polynucleotide kinase and [~,-32P]ATP (Sambrook 
et al., 1989). Primer sequences were as follows: HIV-1 gag (sense), 
5'-ATAATCCACCTATCCCAGTAGGAGAAAT-3'; HIV-1 gag (anti- 
sense), 5'-TTTGGTCCTTGTCTTATGTCCAGAATG-3'; HLA-DQ~ 
(sense), 5'-GTGCTGCAGGTGTAAACTTGTACCAG-3'; HLA-DQe (anti- 
sense), 5'-CACGGATCCGGTAGCAGCGGTAGAGTT-3'. PCR prod- 
ucts were resolved on an 8% polyacrylamide gel and exposed to X-ray 
film. In each experiment, standard controls were included to quantitate 
the PCR product. ACH2 cells (104), which contain a single integrated 
HIV genome per cell (Schnittman et al., 1989), were diluted 10-fold in 
a constant number (2 x 10 s) of uninfected CEM cells. The PCR yielded 
two bands, a gag band (141 bp) and an HLA-DQa band (242 bp), the 
intensity of which is a nonlinear function of the numbers of HiV-1 copies 
and the numbers of cell genome copies, respectively. 
PCR for CMV Genes 
U937 cells (106) were or were not infected with CMV (AD169) and were 
cultured for 1 or 3 days. At each timepoint, cells were lysed to prepare 
either genomic DNA (in 50 ~1 of 10 mM Tris [pH 8.0], 1 mM EDTA, 
0.001% Triton X-100, 0.0001% SDS, 600 #g/ml proteinase K at 56°C 
for 1 hr, followed by 95°C for 15 min) or cDNA from RNA preparations 
of the cells. RNA was extracted after lysis of the U937 cells with RNAzol 
8 (Cinna/Biotecx Laboratories Incorporated). cDNA was prepared in 
a 200 ~1 final volume in 1 x first strand buffer, 5 mM MgCI2, 0.5 mM 
dNTPs, 4 U/p.I RT, 0.5 U/pl RNasin (Promega), and 2.5 p.M d(N)6 (Gene 
Link). 
Genomic DNA and cDNA were used for a 50 I~1 PCR reaction con- 
taining 10 mM Tris (pH 9), 50 mM KCI, 0.01% gelatin, 0.1% Triton 
X-100, 4 mM MgCIz, 0.5 mM dNTPs, 2 U of Taq polymerase (Promega), 
and 10 pmol of each primer. 
PCR primers for iel were as follows: (exon 2), 5'-TTCTATGCCGCA- 
CCATGTCC-3'; (exon 4), 5-'TGGAGTCCTCTGCCAAGAGA-3' (PCR 
fragment is 581 bp for genomic DNA and 297 bp for cDNA); ie2 (exon 
5), 5-'CGTTGTCCAACTCGGAGATG-3'; (exon 5), 5'-ACCACCCTCCT- 
CTTCCCGAT-3' (PCR fragment is 279 bp). 
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